CD274 and breast carcinoma: In contrast to the bispecific Clec9A-PDL1-AFN, administration of Clec9A-PDL1-huIFN, which cannot signal in mouse cells, hardly showed any antitumor efficacy against B16 melanoma (Fig. 5A), in the 4T1 mammary carcinoma s.c. (Fig. 5B) or orthotopic (Fig. 5C) model.